Mallinckrodt considering Chapter 11 bankruptcy protection for generics unit: WSJ

(Reuters) – Drugmaker Mallinckrodt Plc (N:) is considering a Chapter 11 filing covering its U.S. generics business, the Wall Street Journal reported on Monday citing people familiar with the matter. (https://on.wsj.com/3c3rwqH)

The company has begun confidential discussions with creditors and is considering placing its U.S. generic drug business into bankruptcy to address the debt maturities and liabilities arising out of the opioid crisis, the report said.

Mallinckrodt did not immediately respond to Reuters request for comment.

Shares fell about 32% before being halted.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.